ranolazine has been researched along with Cardiovascular Stroke in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 15 (39.47) | 29.6817 |
| 2010's | 18 (47.37) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Barchukov, VV; Gudasheva, TA; Kryzhanovskii, SA; Likhosherstov, AM; Mokrov, GV; Tsorin, IB; Vititnova, MB | 1 |
| Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Schmidt, CW; Storey, KM; Traverse, JH; Wang, J | 1 |
| Blankenberg, S; Deutscher, N; Diermann, N; Friedrich, FW; Radziwolek, L; Schwemer, TF; Sehner, S | 1 |
| Marciniak, TA; Serebruany, V | 1 |
| Ameen, AM; Tawfik, MK | 1 |
| Aidonidis, I; Dipla, K; Hatziefthimiou, A; Moschovidis, V; Simopoulos, V; Stamatiou, R; Stravela, S | 1 |
| Belardinelli, L; Dhalla, AK; Galanopoulos, G; Kostakou, E; Mantzouratou, P; Mourouzis, I; Pantos, C | 1 |
| Hale, SL; Kloner, RA | 2 |
| Bonaca, MP; Braunwald, E; Conrad, MJ; Jarolim, P; Morrow, DA; Murphy, SA; O'Malley, RG; Sabatine, MS | 1 |
| Alexander, KP; Ben-Yehuda, O; Dressler, O; Farzaneh-Far, R; Généreux, P; Iñiguez, A; James, S; Ohman, EM; Osmukhina, A; Shechter, M; Stone, GW; Weisz, G; Zurakowski, A | 1 |
| Basilio Flores, JE; Loza Munárriz, C; Mejia Dolores, JW; Rey Rodriguez, DE; Salazar, CA; Veramendi Espinoza, LE | 1 |
| Conti, CR | 1 |
| Aass, HC; Aronsen, JM; Brørs, O; Haugen, E; Møller, AS; Mørk, HK; Pedersen, J; Sejersted, OM; Sharikabad, MN; Sjaastad, I | 1 |
| Barone, L; Crea, F; Di Monaco, A; Lamendola, P; Lanza, GA; Pisanello, C | 1 |
| Badger, T; Barry, WH; Kadono, T; Matsuoka, N; Rodesch, CK; Rollins, D; Yamada, S; Zhang, XQ | 1 |
| Aroesty, J; Braunwald, E; Budaj, A; Dalby, AJ; Hedgepeth, CM; Mohanavelu, S; Morrow, DA; Qin, J; Scirica, BM; Stone, PH | 1 |
| Hochman, JS; McCabe, CH; Mega, JL; Merlini, P; Morrow, DA; Murphy, SA; Scirica, BM; Sloan, S | 1 |
| Bonaca, M; Braunwald, E; Dalby, A; Jarolim, P; Morrow, DA; Murphy, SA; Sabatine, M; Scirica, B; Spinar, J | 1 |
| Belardinelli, L; Braunwald, E; Hedgepeth, CM; Karwatowska-Prokopczuk, E; Morrow, DA; Qin, J; Scirica, BM; Spinar, J; Verheugt, FW; Wang, W | 1 |
| Reddy, BM; Schwartzbard, AZ; Weintraub, HS | 1 |
| Madias, JE | 1 |
| Ayalloore, SG; LeLorier, P | 1 |
| Custodis, F; Laufs, U | 1 |
| Athanasiadis, A; Sechtem, U | 1 |
| Bonaca, MP; Braunwald, E; Chamberlin, JS; Jarolim, P; Morrow, DA; Murphy, SA; Rhodes, DW; Sabatine, MS; Scirica, BM; Southwick, PC | 1 |
| Armstrong, PW; Borer, JS; Fleming, T; Nissen, SE | 1 |
| Braunwald, E; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Scirica, BM; Skene, A | 1 |
| Braunwald, E; Budaj, A; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Murphy, SA; Scirica, BM; Skene, A; Varshavsky, S; Wolff, AA | 1 |
| Newby, LK; Peterson, ED | 1 |
| Belardinelli, L; Braunwald, E; Gersh, BJ; Hedgepeth, CM; Hod, H; McCabe, CH; Molhoek, P; Morrow, DA; Murphy, SA; Scirica, BM; Verheugt, FW | 1 |
| Melloni, C; Newby, LK | 1 |
| Belardinelli, L; Hale, SL; Kloner, RA; Shryock, JC; Sweeney, M | 1 |
| Hayashida, W; Pouleur, H; Rousseau, MF; van Eyll, C | 1 |
| Black, SC; Driscoll, EM; Gralinski, MR; Lucchesi, BR; McCormack, JG | 1 |
| Aaker, A; Hirai, T; McCormack, JG; Musch, TI | 1 |
| Blackburn, B; Thiemermann, C; Zacharowski, K | 1 |
| SoRelle, R | 1 |
6 review(s) available for ranolazine and Cardiovascular Stroke
| Article | Year |
|---|---|
Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.
Topics: Acetanilides; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Disease Models, Animal; Myocardial Infarction; Necrosis; Piperazines; Ranolazine; Reperfusion Injury; Ventricular Function, Left | 2014 |
Ranolazine for stable angina pectoris.
Topics: Angina, Stable; Cardiovascular Agents; Cause of Death; Humans; Incidence; Middle Aged; Myocardial Infarction; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine | 2017 |
[Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
Topics: Acetanilides; Acute Coronary Syndrome; Angina Pectoris; Animals; Apoptosis; Cell Death; Collateral Circulation; Disease Models, Animal; Humans; Ischemic Preconditioning, Myocardial; Meta-Analysis as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxygen Consumption; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Trimetazidine; Vasodilator Agents | 2009 |
Ranolazine: a new approach to treating an old problem.
Topics: Acetanilides; Angina Pectoris; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Evidence-Based Medicine; Heart Diseases; Heart Failure, Diastolic; Humans; Myocardial Infarction; Piperazines; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2010 |
[Conservative therapy of patients with stable coronary heart disease].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Combined Modality Therapy; Coronary Disease; Drug Incompatibility; Enzyme Inhibitors; Heart Failure; Heart Rate; Humans; Life Style; Myocardial Infarction; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome | 2012 |
Late sodium current inhibition as a new cardioprotective approach.
Topics: Acetanilides; Angina Pectoris; Animals; Blood Pressure; Disease Models, Animal; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels | 2008 |
12 trial(s) available for ranolazine and Cardiovascular Stroke
| Article | Year |
|---|---|
Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.
Topics: Adult; Aged; Angina, Unstable; Coronary Circulation; Feasibility Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Ranolazine; Recovery of Function; Sodium Channel Blockers; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Topics: Acute Coronary Syndrome; Angina Pectoris; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Ranolazine; Risk Assessment; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2019 |
Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Cardiovascular Agents; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Ranolazine; Risk Factors; Sensitivity and Specificity; Troponin I | 2015 |
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Angina Pectoris; Coronary Artery Disease; Coronary Stenosis; Double-Blind Method; Female; Hospitalization; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Ranolazine; Sodium Channel Blockers; Stroke | 2016 |
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarcti
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Electrocardiography, Ambulatory; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Ranolazine; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Angina, Unstable; Death; Electrocardiography; Enzyme Inhibitors; Female; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Prospective Studies; Ranolazine; Risk Factors; Sex Characteristics; Sex Distribution; Surveys and Questionnaires; Thrombolytic Therapy | 2010 |
Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Biomarkers; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Predictive Value of Tests; Prognosis; Prospective Studies; Ranolazine; Risk Factors; Troponin I | 2010 |
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thr
Topics: Acetanilides; Acute Coronary Syndrome; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Follow-Up Studies; Humans; Incidence; Myocardial Infarction; Piperazines; Placebos; Prognosis; Proportional Hazards Models; Ranolazine; Risk Factors; Tachycardia, Ventricular; Thrombolytic Therapy; Ventricular Premature Complexes | 2010 |
Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
Topics: Acetanilides; Acute Disease; Aged; Angina, Unstable; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Ranolazine; Syndrome | 2006 |
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Topics: Acetanilides; Aged; Angina Pectoris; Cardiovascular Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Proportional Hazards Models; Ranolazine; Recurrence | 2007 |
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
Topics: Acetanilides; Acute Disease; Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Diabetic Angiopathies; Electrocardiography; Electrophysiology; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Placebos; Ranolazine; Tachycardia; Thrombolytic Therapy | 2007 |
Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease.
Topics: Acetanilides; Angina Pectoris; Blood Pressure; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Ranolazine; Ventricular Function, Left | 1994 |
20 other study(ies) available for ranolazine and Cardiovascular Stroke
| Article | Year |
|---|---|
Anti-Ischemic Activity of Triamine ALM-802 under Conditions of Endothelial Dysfunction.
Topics: Animals; Electrophysiology; Hyperhomocysteinemia; Isoproterenol; Male; Myocardial Infarction; Ranolazine; Rats; Trimetazidine | 2019 |
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome | 2020 |
Cardioprotective effect of ranolazine in nondiabetic and diabetic male rats subjected to isoprenaline-induced acute myocardial infarction involves modulation of AMPK and inhibition of apoptosis.
Topics: Acute Disease; AMP-Activated Protein Kinases; Animals; Apoptosis; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Experimental; Electrocardiography; Glycated Hemoglobin; Isoproterenol; Male; Myocardial Infarction; Oxidative Stress; Ranolazine; Rats; Rats, Wistar | 2019 |
Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heart Rate; Male; Myocardial Infarction; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Tachycardia, Ventricular; Time Factors; Ventricular Fibrillation | 2020 |
The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats.
Topics: Acetanilides; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Echocardiography; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Heart Function Tests; Insulin; Male; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Wistar; Treatment Outcome; Ventricular Function, Left | 2014 |
The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit.
Topics: Acetanilides; Animals; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Disease Models, Animal; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Piperazines; Rabbits; Ranolazine | 2008 |
Expanding the understanding of the treatment of chronic angina: a 21st century approach-part II.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Chronic Disease; Enzyme Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2008 |
Cardiomyocytes from postinfarction failing rat hearts have improved ischemia tolerance.
Topics: Acetanilides; Adenosine Triphosphate; Animals; Calcium; Cell Death; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Heart Failure; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen; Piperazines; Potassium; Ranolazine; Rats; Rats, Wistar; Rubidium Radioisotopes; Sodium; Sodium Channel Blockers; Sodium-Calcium Exchanger; Sodium-Potassium-Exchanging ATPase; Time Factors | 2009 |
Direct toxic effects of aqueous extract of cigarette smoke on cardiac myocytes at clinically relevant concentrations.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Acetanilides; Angina Pectoris; Animals; Calcium; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Glucose; Heart Ventricles; Mice; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Myocytes, Cardiac; Nicotine; Piperazines; Rabbits; Ranolazine; Reactive Oxygen Species; Smoke; Smoking; Time Factors | 2009 |
Letter by Madias regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-
Topics: Acetanilides; Acute Coronary Syndrome; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Predictive Value of Tests; Ranolazine; Risk Factors; Stroke Volume; Tachycardia, Ventricular; Thrombolytic Therapy | 2011 |
Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Isc
Topics: Acetanilides; Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Predictive Value of Tests; Ranolazine; Risk Factors; Stroke Volume; Tachycardia, Ventricular; Thrombolytic Therapy | 2011 |
[Update coronary artery disease: important progresses in acute and chronic therapy].
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Benzazepines; Coronary Artery Disease; Early Medical Intervention; Humans; Ivabradine; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Ranolazine; Survival Rate; Thrombolytic Therapy | 2012 |
Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Aged, 80 and over; Biomarkers; Cause of Death; Electrocardiography; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Predictive Value of Tests; Pregnancy; Pregnancy-Associated Plasma Protein-A; Prognosis; Prospective Studies; Ranolazine; Recurrence; Risk Assessment; Signal Processing, Computer-Assisted; Survival Analysis; Troponin | 2012 |
Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD.
Topics: Acetanilides; Angina Pectoris; Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Drug Labeling; Humans; Maryland; Myocardial Infarction; Piperazines; Ranolazine | 2004 |
Does ranolazine have a place in the treatment of acute coronary syndromes?
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Enzyme Inhibitors; Humans; Myocardial Infarction; Piperazines; Ranolazine | 2007 |
Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Topics: Acetanilides; Acute Coronary Syndrome; Acute Disease; Angina Pectoris; Cardiovascular Agents; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine; Recurrence; Sex Factors; Thrombolytic Therapy | 2008 |
Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion.
Topics: Acetanilides; Animals; Coronary Circulation; Creatine Kinase; Dogs; Hemodynamics; Infusions, Intravenous; Male; Models, Cardiovascular; Myocardial Infarction; Myocardial Ischemia; Piperazines; Ranolazine; Reperfusion Injury; Risk Factors | 1994 |
Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction.
Topics: Acetanilides; Animals; Blood Glucose; Cardiac Output, Low; Enzyme Inhibitors; Female; Glycogen; Lactic Acid; Muscle, Skeletal; Myocardial Infarction; Physical Exertion; Piperazines; Ranolazine; Rats; Rats, Wistar | 1996 |
Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.
Topics: Acetanilides; Animals; Blood Pressure; Coronary Disease; Coronary Vessels; Disease Models, Animal; Fatty Acids; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Troponin T | 2001 |
Cardiovascular news.
Topics: Acetanilides; Angina, Unstable; Anti-Arrhythmia Agents; Calcium Channel Blockers; Coronary Disease; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolytic Agents; Fondaparinux; Humans; Hydantoins; Imidazoles; Imidazolidines; Multicenter Studies as Topic; Myocardial Infarction; Nicorandil; Piperazines; Polysaccharides; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome | 2001 |